Edition:
United States

SciClone Pharmaceuticals Inc (SCLN.OQ)

SCLN.OQ on NASDAQ Stock Exchange Global Select Market

9.35USD
26 May 2017
Change (% chg)

$0.05 (+0.54%)
Prev Close
$9.30
Open
$9.35
Day's High
$9.43
Day's Low
$9.20
Volume
42,337
Avg. Vol
56,355
52-wk High
$15.02
52-wk Low
$8.60

Latest Key Developments (Source: Significant Developments)

Sciclone reports Q1 revenue $42.9 million
Wednesday, 10 May 2017 04:05pm EDT 

May 10 (Reuters) - Sciclone Pharmaceuticals Inc :Sciclone reports first quarter 2017 financial results.Q1 revenue rose 18 percent to $42.9 million.Q1 non-GAAP earnings per share $0.31.Q1 GAAP earnings per share $0.28.  Full Article

Sciclone Pharma files for mixed shelf of upto $100 mln
Thursday, 9 Mar 2017 04:53pm EST 

Sciclone Pharmaceuticals Inc :Sciclone Pharmaceuticals Inc - files for mixed shelf of upto $100 million - SEC filing.  Full Article

SciClone reports Q4 revenue of $44.1 million
Monday, 6 Mar 2017 06:00am EST 

SciClone Pharmaceuticals Inc : SciClone reports 2016 financial results and 2017 outlook . Q4 revenue rose 3 percent to $44.1 million . Sees FY 2017 non-GAAP earnings per share $0.60 to $0.64 . Q4 non-GAAP earnings per share $0.20 . Q4 GAAP earnings per share $0.12 . Sees FY 2017 revenue $170 million to $175 million . SciClone Pharmaceuticals Inc- SciClone projects its 2017 revenue to be in range between $170 and $175 million .SciClone Pharmaceuticals - Further expects that pricing pressures on revenue in 2017 to be offset through sharing of burden with China distributors.  Full Article

Sciclone says received unsolicited proposal from GL Capital and ABG Management
Monday, 14 Nov 2016 04:05pm EST 

Sciclone Pharmaceuticals Inc : Sciclone confirms receipt of unsolicited proposal from GL Capital and ABG Management . Sciclone Pharmaceuticals Inc - got proposal to acquire outstanding shares of Sciclone not already owned by consortium for $11.18 per share in cash .Sciclone Pharmaceuticals Inc - board of directors will carefully review and consider proposal.  Full Article

Gl management and its affiliates submit proposal to board of Sciclone Pharmaceuticals
Monday, 14 Nov 2016 07:03am EST 

Sciclone Pharmaceuticals Inc : Gl Management And Its Affiliates submit proposal to board of Sciclone Pharmaceuticals Inc to buyout the Co at $11.18 per share in cash . Gl management and affiliates - consortium intends to finance acquisition through combination of debt and equity financing . Gl partners capital management and affiliates own 9.3 percent stake in sciclone pharmaceuticals - sec filing . Gl management and its affiliates say it is part of consortium that includes abg management limited and its affiliates making a bid for sciclone pharma .Gl management and affiliates-consortium indicated in proposal that prepared to expeditiously negotiate, finalize terms of acquisition in definitive agreements.  Full Article

SciClone sees FY 2016 non-gaap EPS $0.70 to $0.74
Tuesday, 9 Aug 2016 04:05pm EDT 

Sciclone Pharmaceuticals Inc : Sciclone reports second quarter 2016 financial results . Sees fy 2016 non-gaap earnings per share $0.70 to $0.74 . Q2 gaap earnings per share $0.12 . Q2 revenue rose 3 percent to $39 million . Q2 non-gaap earnings per share $0.20 .Sees fy 2016 revenue $158 million to $163 million.  Full Article

Sciclone Pharmaceuticals plans to remain independent publicly traded company
Tuesday, 19 Jul 2016 06:00am EDT 

Sciclone Pharmaceuticals Inc : No longer continuing active discussions with potential acquirers . Expects that non-gaap earnings per share on a fully diluted basis to be in range of $0.70 to $0.74 for year . Plans to remain independent publicly traded co as it continues to execute on strategic growth plan for core commercial business . "none of bids under discussion reflected a premium to company's recent trading price" . During review part of process, company did receive interest from a number of prospective acquirers . Sciclone provides update on strategic review process . Sees FY 2016 non-gaap earnings per share $0.70 to $0.74 . Sees FY 2016 revenue $158 million to $163 million . Plans to remain an independent publicly traded company . Guidance for full-year 2016 financial results. Company expects 2016 revenues to be in range of $158 million to $163 million . Board will continue to evaluate additional strategic opportunities while continuing to focus on growing company's business .Discussions ended without an offer board was willing to pursue.  Full Article

SciClone Pharmaceuticals Inc reaffirms FY 2015 revenue guidance; raises FY 2015 EPS guidance
Monday, 9 Nov 2015 04:05pm EST 

SciClone Pharmaceuticals Inc:Raises FY 2015 non-GAAP EPS guidance to between $0.93 and $0.97, up from its original guidance of between $0.73 and $0.77.Says FY 2015 revenue guidance of between $153 million and $158 million remains unchanged.  Full Article

SciClone Pharmaceuticals Inc reaffirms FY 2015 guidance
Monday, 10 Aug 2015 04:01pm EDT 

SciClone Pharmaceuticals Inc:Maintains FY 2015 revenue guidance of between $153 million and $158 million and non-GAAP EPS guidance of between $0.73 and $0.77.FY 2015 revenue of $155 million and EPS of $0.51 - Thomson Reuters I/B/E/S.  Full Article

More From Around the Web

BRIEF-Sciclone reports Q1 revenue $42.9 million

* Q1 GAAP earnings per share $0.28 Source text for Eikon: Further company coverage: